​

Funding Round

Series C - Moximed

Series C - Moximed

Investment Firm

Overview

Moximed improves the standard of care for patients with osteoarthritis and investigates therapies to treat affected joints.

Announced Date

Aug 16, 2022

Funding Type

Series C

Highlights

Location

United States, North America

Social

Investor Lead

Advent Life Sciences

Advent Life Sciences

Advent Life Sciences is a early_stage_venture and late_stage_venture and seed and venture firm.

Participant Investors

7

Investor Name
Participant InvestorGBS Ventures
Participant InvestorAdvent Life Sciences
Participant InvestorMorgenthaler Ventures
Participant InvestorVertex Ventures
Participant InvestorNew Enterprise Associates

Round Details and Background

Moximed raised $40000000 on 2022-08-16 in Series C

Moximed improves the standard of care for patients with osteoarthritis and investigates therapies to treat affected joints.

Company Funding History

8

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 27, 2016
Series B - Moximed
3-12.6M
May 07, 2015
Series B - Moximed
6-33.0M
Jan 01, 2012
Venture Round - Moximed
4-1.8M
Dec 05, 2011
Series A - Moximed
-45.8M

Recent Activity

There is no recent news or activity for this profile.